Key network approach reveals new insight into Alzheimer's disease. Issue 4 (1st August 2014)

• Record Type: Journal Article
• Authors: Schluesener, Jan K.; Zhu, Xiaomei; Schluesener, Hermann J.; Wang, Gao‐Wei; Ao, Ping
• Is Part Of: IET systems biology. Volume 8:Issue 4(2014)
• Page Start: 169
• Page End: 175
• Publication Date: 2014-08-01
• Subjects: diseases -- medical disorders -- neurophysiology -- enzymes -- molecular biophysics -- biochemistry -- patient treatment -- bioinformatics -- medical computing; Alzheimer’s disease -- neurodegenerative disorder -- amyloid beta -- TAU -- beta‐secretase -- glutamate -- cyclin‐dependent kinase 5 -- phosphoinositide 3‐kinase -- hypoxia‐induced factor 1 alpha -- pathogenesis -- feedback loops -- pathway interconnections -- closed network -- pathological molecular processes -- systems biology approach; Systems biology -- Periodicals; Cell physiology -- Periodicals; Biological systems -- Mathematical models -- Periodicals; Genetics -- Mathematical models -- Periodicals; Computational biology -- Periodicals; 573
• DOI: 10.1049/iet-syb.2013.0047
• Languages: English
• ISSNs: 1751-8849

Abstract

Abstract : Alzheimer's disease (AD) is a severe neurodegenerative disorder without curative treatment. Extensive data on pathological molecular processes have been accumulated over the last years. These data combined allows a systems biology approach to identify key regulatory elements of AD and to establish a model descriptive of the disease process which can be used for the development of therapeutic agents. In this study, the authors propose a closed network that uses a set of nodes (amyloid beta, tau, beta‐secretase, glutamate, cyclin‐dependent kinase 5, phosphoinositide 3‐kinase and hypoxia‐induced factor 1 alpha) as key elements of importance to the pathogenesis of AD. The proposed network, in total 39 nodes, is able to become a novel tool capable of providing new insights into AD, such as feedback loops. Further, it highlights interconnections between pathways and identifies their combination for therapy of AD.